Rhythm Pharmaceuticals enters the back half of the week trading 10% higher, powered by a strong Q1 earnings beat that sent analysts scrambling to revise their models upward — while shorts hold their ground at the highest level in months.
The week's defining move was Tuesday's 7.9% surge to $92.31, itself the continuation of a broader 10% gain across the past five sessions. Q1 results landed above expectations, with multiple sell-side desks raising price targets the same day results dropped. Wells Fargo lifted its target to $144, maintaining Overweight. RBC Capital moved to $137, keeping Outperform. Both revisions landed on May 6, the morning after earnings. The consensus mean target now sits at $137.87 — implying roughly 49% upside from the current price and suggesting the Street remains firmly bullish on Rhythm's trajectory. That gap is the key tension: a stock rallying hard after a clean quarter, yet still trading nearly 33% below what analysts collectively think it's worth.
The short interest picture complicates that optimism. Bears have built steadily since early April. Short interest jumped roughly 24% over the past month, rising from around 6.5 million shares to just over 8 million, equivalent to 12% of the free float. That's a material position for a specialty biotech. Yet the borrow market tells a different story: cost to borrow runs at 0.47% annualised — effectively free — and availability remains loose, with utilisation far below its 52-week peak of 10.6%. Short sellers have been accumulating, but they're not paying a squeeze premium to do so. Options positioning reinforces the calm: the put/call ratio is at 0.12, near its lowest reading of the past year and barely above the 20-day average of 0.11. Call demand dominates, consistent with the bullish momentum after earnings — this is not a crowd bracing for downside.
The bull case rests on IMCIVREE, Rhythm's MC4R agonist franchise for rare genetic obesity. Revenue growth has been consistent, and last year's expansion into hypothalamic obesity opened a meaningfully larger addressable market. The Prader-Willi Syndrome programme is the next potential catalyst. Bears point to execution risk on the IMCIVREE sales ramp, the risk of disappointment in earlier-stage assets, and long-term dilution. With the stock still loss-making — trailing P/E is deeply negative and EV/EBITDA is around -40x — valuation is entirely a pipeline story. Forward earnings momentum is strong, ranking in the 83rd percentile for 12-month forward EPS year-on-year improvement, but EPS momentum over the past 30 days is in the 14th percentile, indicating near-term estimate revisions have been muted. Rhythm is also scheduled to present at the Bank of America Global Healthcare Conference, providing another near-term venue for management to shape the narrative around PWS data and commercial execution.
Institutional ownership shows broad-based support. RA Capital holds 9.8% as lead dedicated healthcare manager. Vanguard added more than 1.2 million shares as of end-March. JP Morgan Asset Management increased its position by over 376,000 shares in the same period. Insider activity is less compelling: the CFO sold shares across multiple tranches in February at prices around $100-103, and the Chief Accounting Officer sold in early March near $89. Those sales predate the Q1 beat and may reflect routine planning, but the net insider position over 90 days turned mildly positive on a shares basis due to equity awards, not open-market buying. That combination — institutions adding, insiders selling before earnings — is a neutral rather than directional signal.
With the next earnings event pencilled for June 24, the near-term story pivots from quarterly numbers to any incremental data or conference commentary on the PWS programme. Short interest at 12% of float is elevated enough to fuel a meaningful covering rally if the thesis continues to build — but with borrow freely available and options traders positioned bullishly, there is no indication yet that bears are under pressure to move.
See the live data behind this article on ORTEX.
Open RYTM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
